King buys Jones in $3.2bn stock transaction
Executive Summary
King Pharmaceuticals is acquiring Jones Pharma in an all-stock pooling-of-interests transaction that values Jones at $3.2bn. Each common share of Jones will be exchanged for 1.125 shares of King common, a premium of (pr)16% based on their 10-day pre-announcement market averages.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice